Drug news
Levodopa-carbidopa gel (Abbott) Phase III results
The results were announced from a Phase III trial evaluating the levodopa-carbidopa intestinal gel (LCIG) from Abbott Labs for advanced Parkinsons Disease. The study showed that patients treated with LCIG for 12 weeks reported clinically meaningful and statistically significant improvements in "off" time compared to levodopa-carbidopa immediate release (IR) tablets, without increasing troublesome dyskinesia. "Off" time refers to the periods of poor mobility, slowness and stiffness experienced by patients with Parkinson's disease. The results from the study will be presented as part of the Emerging Science program (formerly known as Late-Breaking) at the American Academy of Neurology's 64th Annual Meeting in New Orleans on April 25.